Skip to content

Subpart F at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
-2.1%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
-$24.35M
Baxter International logo
Baxter InternationalBAX
$4.5M-30.8%
Cadence Design Systems logo
Cadence Design SystemsCDNS
$5.51M
GE Vernova logo
GE VernovaGEV
$20.25M
Cadence Design Systems logo
Cadence Design SystemsCDNS
1.4%

Other financials

Income statement

See full
Revenue$231.3M+34.2%
Gross profit$107.2M+29.9%
Operating income$36.2M+40.3%
Net income$17.3M-15.1%
EPS (diluted)$0.24-20.0%

Balance sheet

See full
Cash & equivalents$894.1M+91.1%
Total debt$323.8M+91.3%
Total equity$1.6B+66.6%
Total assets$3.1B+58.5%

Cash flow

See full
Operating cash flow-$29.5M-659%
CapEx$22.2M+32.7%
Free cash flow-$51.7M-352%

Valuation

See full
Market cap$7.59B+75.5%
Enterprise value$7.02B+71.6%
P/E83.4×+42.8×
P/S7.9×+2.5×

Profitability

See full
Gross margin44.2%-5.0pp
Operating margin12.5%-6.4pp
Net margin9.5%-3.8pp
FCF margin-1.1%-0.5pp

Returns & leverage

See full
Return on equity7.2%-5.0pp
Debt / equity0.2×0.0×
Current ratio3.5×+1.1×

Where this comes from

Reported directly by ACM Research in its filing.

Tagged under the XBRL concept acmr:EffectiveIncomeTaxRateReconciliationCrossBorderSubpartFAmount.

The official record: ACM Research’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about ACM Research's subpart f.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ACM Research's subpart f?
ACM Research (ACMR) reported subpart f of $562.75K in Q4 2025.
What does subpart f mean?
Refers to the tax impact of Subpart F income, which represents specific types of passive or easily movable income earned by controlled foreign corporations. This is a key component of the U.S. anti-deferral tax regime.